Hookipa Pharma Announces IPO Plans with 6.7 Million Shares at $14 to $16 Each, Raising $100.5 Million

Hookipa Pharma plans to offer 6.7 million shares in its IPO, priced between $14 and $16 each, raising $100.5 million at the midpoint. The company will use the proceeds for clinical trials and R&D for its next-generation programs. BofA Merrill Lynch, SVB Leerink, and RBD are joint bookrunners, with Kempen acting as co-manager. Hookipa Pharma will list on Nasdaq under the ticker symbol "HOOK."